Insight Molecular Diagnostics vs Anbio Biotechnology
IMDX and NNNN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IMDX and NNNN compare
Anbio Biotechnology grew revenue faster over the last twelve months (5.6% versus −60.8% for Insight Molecular Diagnostics).
Anbio Biotechnology keeps more of each dollar of sales as profit, with a net margin of 74.1% compared with −2956% at Insight Molecular Diagnostics.
Anbio Biotechnology scores higher on the StockData Score (11 against 7 for Insight Molecular Diagnostics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IMDX | NNNN |
|---|---|---|
| Size and price | ||
| Market cap | $70.0M | – |
| Share price | $2.14 | $3.82 |
| Change, 1 year | −74.8% | −83.0% |
| Change, 5 years | −96.1% | – |
| Beta (5Y) | 1.10 | 1.55 |
| Employees | 58 | 27 |
| StockData Score | ||
| Total score | 7 | 11 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 1 | 5 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 41.9× | – |
| FCF yield | −44.3% | – |
| Growth | ||
| Revenue growth (TTM) | −60.8% | 5.6% (better) |
| Revenue growth, 5Y average | 27.2% | – |
| Net income growth (TTM) | – | 170% |
| EPS growth (TTM) | – | 163% |
| Profitability | ||
| Gross margin | 48.3% | 87.2% (better) |
| Operating margin | −3012% | 66.7% (better) |
| Net margin | −2956% | 74.1% (better) |
| FCF margin | −1856% | – |
| Return on equity | – | 27.0% |
| Return on invested capital | – | 48.7% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 2.00 | 344.31 (better) |
| Altman Z-score | −24.13 | – |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | −37.2% | – |
| Shareholder yield | −37.2% | – |
| Ownership | ||
| Held by institutions | 56.4% | – |
| Held by insiders | 81.6% | 0.00% |
| Insider net buying, 12 months | $5.7M | – |
| Short interest, % of float | 17.0% | 0.02% |
Go deeper
- IMDX stock overview
- IMDX income statement
- IMDX valuation and score
- NNNN stock overview
- NNNN income statement
- NNNN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.